Related Experiment Video

Updated: Jul 13, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Treatment of ventricular dysrhythmias and sudden cardiac death: a guideline-based approach for patients with chronic

Ayesha Hasan1, Clyde W Yancy

  • 1Division of Cardiovascular Medicine, Heart Failure Devices Clinic, Ohio State University College of Medicine, Columbus, OH 43210-1252, USA. ayesha.hasan@osumc.edu

Congestive Heart Failure (Greenwich, Conn.)
|August 4, 2007
PubMed

Insights

New guidelines help identify chronic heart failure patients benefiting from implantable defibrillator therapy for ventricular arrhythmia prevention. This review compares recent joint statements with prior guidelines, focusing on expanded primary prevention criteria.

Area of Science:

  • Cardiology
  • Electrophysiology

Background:

  • Device therapy, including implantable defibrillators, is increasingly used for chronic heart failure patients at risk of ventricular arrhythmia.
  • Evolving knowledge and new data have led to updated recommendations from major international cardiology societies.

Purpose of the Study:

  • To compare the recent joint guideline statement from ACC, AHA, and ESC with previous guidelines (HFSA 2006, ACC/AHA 2005) regarding ventricular arrhythmia and sudden cardiac death prevention.
  • To emphasize expanded criteria for primary prevention in ischemic and nonischemic heart disease.
  • To review electrophysiology testing guidelines and the role of microvolt T-wave alternans in risk stratification for patients with left ventricular dysfunction.

Main Methods:

  • Comparative analysis of guideline statements from the American College of Cardiology (ACC), American Heart Association (AHA), European Society of Cardiology (ESC), and Heart Failure Society of America (HFSA).
  • Focus on updated recommendations for primary prevention of sudden cardiac death in heart failure patients.
  • Review of current practices in electrophysiology testing and emerging risk stratification tools.

Main Results:

  • The recent joint guideline statement introduces expanded criteria for primary prevention of sudden cardiac death in patients with left ventricular dysfunction.
  • Variances in recommendations between guidelines necessitate careful consideration for patient management.
  • Microvolt T-wave alternans is highlighted as an emerging tool for risk stratification.

Conclusions:

  • Updated guidelines provide refined criteria for implantable defibrillator therapy in chronic heart failure patients at risk of ventricular arrhythmia.
  • Comparative analysis aids clinicians in navigating differing recommendations for primary prevention.
  • Further evaluation of electrophysiology testing and novel risk stratification methods is warranted.

More Related Videos

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine05:36

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...